West Pharmaceutical Services, Inc.

As of October 17, 2025, West Pharmaceutical Services, Inc. is considered expensive and overvalued with a P/E ratio of 33, compared to peers, and has underperformed the S&P 500 year-to-date, raising concerns about its valuation outlook.

As of October 17, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a valuation grade of "expensive," reflected by a high P/E ratio of 33 and a year-to-date decline of 17.39%, despite a recent positive stock performance.

As of October 10, 2025, West Pharmaceutical Services, Inc. is considered overvalued with a P/E ratio of 33, higher than its peers, and has underperformed the S&P 500 with a return of -9.76% over the past year.

As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, but mixed signals suggest caution due to recent underperformance compared to the S&P 500.

As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, outperforming the S&P 500 recently, but caution is advised due to mixed signals in longer-term performance.

As of October 3, 2025, West Pharmaceutical Services, Inc. shows a bullish trend with positive momentum indicators, although caution is advised due to some bearish signals, while it has outperformed the S&P 500 recently but underperformed over longer periods.

As of May 27, 2025, West Pharmaceutical Services, Inc. has a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -22.16% versus the index's 12.22%.

As of April 30, 2025, West Pharmaceutical Services, Inc. is fairly valued with a P/E ratio of 33, an EV to EBITDA of 21.43, and an ROE of 18.49%, while its stock has underperformed the S&P 500 with a year-to-date return of -33.84%.

As of May 27, 2025, the market trend is mildly bearish, with daily moving averages and weekly Dow Theory indicating bearish sentiment, while mixed signals from the MACD and RSI suggest a cautious outlook with potential for recovery.

As of March 2022, the management team of West Pharmaceutical Services, Inc. includes Patrick Zenner (Independent Chairman), Eric Green (CEO), and several Independent Directors: Mark Buthman, William Feehery, Robert Friel, Thomas Hofmann, and Paula Johnson. They are responsible for the company's strategic direction and operations.

West Pharmaceutical Services, Inc. manufactures packaging components and delivery systems for injectable drugs, with net sales of $698 million and a market cap of approximately $15.93 billion as of March 2025. Key financial metrics include a P/E ratio of 33.00 and a dividend yield of 0.38%.

As of Jun 18, West Pharmaceutical Services, Inc. has a market capitalization of $15.93 billion, with net sales of $2.90 billion and a net profit of $467.20 million over the latest four quarters. The company reported shareholder's funds of $2.68 billion and total assets of $3.64 billion as of Dec 24.